Introduction: Aspirin is the most frequently used antiplatelet therapy after percutaneous coronary intervention
(PCI). Yet, the optimal daily dose of aspirin is unanswered.
Objectives: We aimed to compare the effect of high-dose versus low-dose aspirin in a randomized trial of
patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI.
Patients and Methods: In a double-blind randomized trial, 175 patients with STEMI were randomly assigned to
high-dose or low-dose aspirin. The primary efficacy outcome was major adverse cardiovascular events (MACE)
as a composite endpoint of death, myocardial infarction, stroke and revascularization procedures. The primary
safety endpoint was major bleeding.
Results: Totally 90 and 85 patients were assigned to high-dose and low-dose aspirin, respectively. The incidence
rate of MACE was 13.1 and 10.1 per 100 person year in high-dose and low dose aspirin, respectively. There was
no significant difference between high-dose and low-dose aspirin in terms of efficacy (Adjusted hazard ratio:
0.85, 95% CI=0.29-2.45) and safety outcome (Adjusted hazard ratio: 1.65, 95% CI=0.41-6.69).
Conclusion: Efficacy and safety outcomes were not significantly different between high-dose and low-dose